Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases

Nature Cell Biology

Volumn 9, Issue 4, 2007, Pages 402-414

  Qi, Mei Ling ^a,g   Tagawa, Kazuhiko ^a   Enokido, Yasushi ^a   Yoshimura, Natsue ^a   Wada, Yo ichi ^a   Watase, Kei ^a   Ishiura, Sho ichi ^b   Kanazawa, Ichiro ^c   Botas, Juan ^d   Saitoe, Minoru ^e   Wanker, Erich E ^f   Okazawa, Hitoshi ^a,b,e,g  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c National Institute of Mental Health   (Japan)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; HUNTINGTIN; MUTANT PROTEIN; NUCLEAR PROTEIN; PROTEOME;

ANIMAL CELL; ARTICLE; CELL INCLUSION; CELL NUCLEUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DROSOPHILA; FETUS; GENOTOXICITY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; NERVE CELL; NONHUMAN; PATHOLOGY; POLYGLUTAMINE DISEASE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; BLOTTING, WESTERN; CELL DEATH; CELLS, CULTURED; DROSOPHILA; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HMGB1 PROTEIN; HMGB2 PROTEIN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEURONS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN BINDING; PROTEOMICS; PURKINJE CELLS; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34047130772     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1553     Document Type: Article

References (50)

1. Gusella, J. F. & MacDonald, M. E. Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease. Nature Rev. Neurosci, 1, 109-115 (2000).
2. Zoghbi, H. Y. & Orr, H. T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
3. Ross, C. A. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 35, 819-822 (2002).
4. Taylor, J. P., Hardy, J. & Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
5. Bonini, N. M. Chaperoning brain degeneration. Proc. Natl Acad. Sci. USA 99, S16407-S16311 (2002).
6. Muchowski, P. J. & Wacker J. L. Modulation of neurodegeneration by molecular chaperones. Nature Rev. Neurosci. 6, 11-22 (2005).
7. Orr, H. T. Beyond the Qs in the polyglutamine diseases. Genes Dev. 15, 925-932 (2001).
8. Venkatraman, P., Wetzel, R., Tanaka, M., Nukina, N. & Goldberg AL. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell. 14, 95-104 (2004).
9. Panov, A. V. et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neurosci. 5, 731-736 (2002).
10. Li, H., Li, S. H., Johnston, H., Shelbourne, P. F. & Li, X. J. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nature Genet. 25, 385-389 (2000).
11. Gauthier, L. R. et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138 (2004).
12. Sugars, K. L. & Rubinsztein, D. C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19, 233-238 (2003).
13. Klement, I. A. et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 95, 41-53 (1998).
14. Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66 (1998).
15. Steffan, J. S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 413, 739-743 (2001).
16. McCampbell, A. et al. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl Acad. Sci. USA 98, 15179-15184 (2001).
17. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041-2046 (2003).
18. Katsuno, M. et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature Med. 9. 768-773 (2003).
19. Dignam, J. D., Lebovitz, R. M. & Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11, 1475-1489 (1983).
20. Agresti, A. & Bianchi, M. E. HMGB proteins and gene expression. Curr. Opin. Genet Develop. 13, 170-178 (2003).
21. Travers A. E. Priming the nucleosome: A role for HMGB proteins? EMBO Rep. 4, 131-136 (2003).
22. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90, 549-558 (1997).
23. Perutz, M. F., Pope B. J., Owen, D., Wanker, E. E. & Scherzinger, E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagines-rich domains of Sup35 and of the amyloid β-peptide of amyloid plaques. Proc. Natl Acad. Sci. USA 99, 5596-5600 (2002).
24. Ross, C. A., Poirier, M. A., Wanker, E. E. & Amzel, M. Polyglutamine fibrilogenesis: The pathway unfolds. Proc. Natl Acad. Sci. USA 100, 1-3 (2003).
25. Tagawa, K. et al. Distinct aggregation and cell death patterns among different types of primary neurons induced by mutant huntingtin protein. J. Neurochem. 89, 974-987 (2004).
26. Hoshino, M., Tagawa, K., Okuda, T. & Okazawa H. General transcriptional repression by polyglutamine disease proteins is not directly linked to the presence of inclusion bodies. Biochem. Biophys. Res. Commun. 313, 110-116 (2004).
27. Fernandez-Funez, P. et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101-106 (2000).
28. Jackson, G. R. et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21, 633-642 (1998).
29. Hoshino, M. et al. Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. J. Cell Biol. 172, 589-604 (2006).
30. Bae, B.-II. et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41 (2005).
31. Sancar, A., Lindsay-Boltz, L. A., Unsal-Kacmaz, K. & Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoint. Annu. Rev. Biochem. 73, 39-85 (2004).
32. Sengupta, S. & Harris, C. C. p53: Traffic cop at the crossroads of DNA repair and recombination. Nature Rev. Mol. Cell Biol. 6, 44-55 (2005).
33. Ohndorf, U.-M., Rould, M. A., He, Q., Pabo, C. O. & Lippard, S. J. Basis for recognition of cisplatin-modified DNA by high mobility group proteins. Nature 399, 708-712 (1999).
34. Jayaraman, L. et al. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 12, 462-472 (1998).
35. Zhang, Y. et al. Reconstitution of 5′-directed human mismatch repair in a purified system. Cell 122, 693-705 (2005).
36. Giavara, S. et al. Yeast Nph6A/B and mammalian Hmgb1 facilitate the maintenance of genome stability. Curr. Biol. 15, 68-72 (2005).
37. Bianchi, M. E. & Beltrame, M. Flexing DNA: HMG-box proteins and their partners. Am. J. Hum. Genet. 63, 1573-1577 (1998).
38. Schaffar G. et al. Cellular toxicity of polyglutamine expansion proteins: Mechanism of transcription factor deactivation. Mol. Cell 15, 95-105 (2004).
39. Zhai, W., Jeong, H., Cui, L., Krainc, D. & Tjian, R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123, 1241-1253 (2005).
40. Okazawa, H. et al. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34, 701-713 (2002).
41. Arrasate, M., Mitra, S., Schweitzer, E. S. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2005).
42. Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551-5560 (2003).
43. de Chiara, C. et al. The AXH module: An independently folded domain common to ataxin-1 and HBP1. FEBS Lett. 551, 107-112 (2003).
44. Chen, Y. W., Allen, M. D., Veprintsev, D. B., Lowe, J. & Bycroft, M. The structure of the AXH domain of spinocerebellar ataxin-1. J. Biol. Chem. 279, 3758-3765 (2004).
45. Calogero, S. et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycemia in newborn mice. Nature Genet. 22, 276-280 (1999).
46. Okamoto, K., Okazawa, H., Okuda, A., Muramatsu, M. & Hamada, H. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. Cell 60, 461-472 (1990).
47. Watase, K. et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919 (2002).
48. Hirai, H. & Launey, T. The regulatory connection between the activity of granule cell NMDA receptors and dendritic differentiation of cerebellar Purkinje cells. J. Neurosci. 20, 5217-5224 (2000).
49. Dura, J. M., Preat, T. & Tully, T. Identification of linotte, a new gene affecting learning and memory in Drosophila melanogaster. J. Neurogenet. 9, 1-14 (1993).
50. Rubin, G. M. & Spradling, A. C. Genetic transformation of Drosophila with transposable element vectors. Science. 218, 348-353 (1982).